Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19

NRx Pharmaceuticals (NASDAQ:NRXP) has received a first safety report from a Southwestern hospital where physicians have administered Zyesami (Aviptadil) to patients with COVID-19 respiratory failure. 

  • These patients were treated under the Federal Right to Try Law, which gives access to investigational medicines for patients who have tried all approved treatment options and cannot participate in a clinical trial to access certain unapproved treatments. 
  • The safety update report indicated that of the first 19 patients treated by December 31, 2021, three had died, and 16 (84%) were reported to be alive by January 22, 2021. 
  • 14 of these 16 patients had been discharged, and two remained in the hospital. 
  • No Serious Adverse Events related to Zyesami were reported. 
  • Related: NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights.
  • These data were included in an application to FDA for Emergency Use Authorization for patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir. 
  • NRx will continue to update the safety database collected under the Right to Try law on an ongoing basis. 
  • Zyesami continues to be tested in the ongoing NIH-sponsored ACTIV-3b trial that has now accrued two-thirds of its targeted enrollment.
  • Price Action: NRXP shares are up 3.47% at $3.28 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.